Candriam SCA’s Arbutus Biopharma ABUS Stock Holding History

Candriam SCA’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-105,000	Closed	-$376K	–	809
2019 Q1	$376K	Hold	105,000	–	–	﹤0.01%	748
2018 Q4	$402K	Hold	105,000	–	–	0.01%	716
2018 Q3	$992K	Buy	+105,000	New	+$1.04M	0.01%	625
2016 Q1	–	Sell	-100,000	Closed	-$445K	–	636
2015 Q4	$445K	Sell	100,000 -67,600	-40%	-$371K	0.01%	473
2015 Q3	$1.02M	Sell	167,600 -14,400	-8%	-$128K	0.03%	433
2015 Q2	$2.16M	Hold	182,000	–	–	0.04%	352
2015 Q1	$3.18M	Buy	+182,000	New	+$3.73M	0.06%	327

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Candriam SCA's ABUS Position: Q2 2019 in Review

Candriam SCA sold out of Arbutus Biopharma (ABUS) in Q2 2019, closing a stake of 105,000 shares — an estimated $376K sold.

Candriam SCA first reported a position in ABUS in Q1 2015 and held it in 7 quarters. The position peaked at $3.18M in Q1 2015. 62 funds tracked by Wall St. Rank hold ABUS as of Q2 2019.

Candriam SCA reported no remaining Arbutus Biopharma position as of Q2 2019 after selling out during the quarter.
Candriam SCA sold 105,000 Arbutus Biopharma shares in Q2 2019, an estimated $376K.
Candriam SCA first reported a position in Arbutus Biopharma in Q1 2015 and held it in 7 quarters.
Candriam SCA's Arbutus Biopharma position peaked at $3.18M in Q1 2015.
62 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2019.

Based on Candriam SCA's 13F filing for Q2 2019, filed 1 Aug 2019.